PDF herunterladen
Semin Plast Surg 2021; 35(03): 145-152
DOI: 10.1055/s-0041-1731461
Review Article

Current Advances in Hypertrophic Scar and Keloid Management

Natasha Barone
1   Faculty of Medicine and Health Sciences, McGill University, Montreal, Canada
,
Tyler Safran
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Joshua Vorstenbosch
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Peter G. Davison
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Sabrina Cugno
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
,
Amanda M. Murphy
2   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Canada
3   Division of Plastic and Reconstructive Surgery, Jewish General Hospital, Montreal, Canada
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Hypertrophic scars and keloids are caused by excessive tissue response to dermal injury due to local fibroblast proliferation and collagen overproduction. This response occurs because of pathologic wound healing due to dysregulation in the inflammatory, proliferative, and/or remodeling phase. Patients with hypertrophic scars or keloids report reduced quality of life, physical status, and psychological health. Hypertrophic scars or keloids will develop in 30 to 90% of individuals, and despite their prevalence, treatment remains a challenge. Of the treatments currently available for hypertrophic scars and keloids few have been adequately supported by studies with appropriate experimental design. Here, we aim to review the available literature to provide up-to-date information on the etiology, epidemiology, histology, pathophysiology, prevention, and management options available for the treatment of hypertrophic scars and keloids and highlight areas where further research is required.

Keywords

scarring - fibrosis - keloid - hypertrophic scar


Publikationsverlauf

Artikel online veröffentlicht:
15. Juli 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Zhu Z, Ding J, Tredget EE. The molecular basis of hypertrophic scars. Burns Trauma 2016; 4: 2-2
    PubMedGoogle Scholar
  • 2 Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297 (10) 433-438
    CrossrefPubMedGoogle Scholar
  • 3 Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci 2018; 19 (03) E711-E711
    CrossrefPubMedGoogle Scholar
  • 4 Monstrey S, Middelkoop E, Vranckx JJ. et al. Updated scar management practical guidelines: non-invasive and invasive measures. J Plast Reconstr Aesthet Surg 2014; 67 (08) 1017-1025
    CrossrefPubMedGoogle Scholar
  • 5 Baisch A, Riedel F. Hyperplastic scars and keloids. Part I: basics and prevention [in German]. HNO 2006; 54 (11) 893-904 , quiz 905
    CrossrefPubMedGoogle Scholar
  • 6 Aarabi S, Longaker MT, Gurtner GC. Hypertrophic scar formation following burns and trauma: new approaches to treatment. PLoS Med 2007; 4 (09) e234-e234
    CrossrefPubMedGoogle Scholar
  • 7 Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 2014; 40 (07) 1255-1266
    CrossrefPubMedGoogle Scholar
  • 8 Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg 2017; 43 (Suppl 1): S3-S18
    CrossrefPubMedGoogle Scholar
  • 9 Mustoe TA, Cooter RD, Gold MH. et al; International Advisory Panel on Scar Management. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110 (02) 560-571
    CrossrefPubMedGoogle Scholar
  • 10 Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the pathophysiology of hypertrophic scars and keloids: how do they differ?. Adv Skin Wound Care 2018; 31 (01) 582-595
    CrossrefPubMedGoogle Scholar
  • 11 Carswell L, Borger J. Hypertrophic Scarring Keloids. Treasure Island, FL: StatPearls; 2021
    Google Scholar
  • 12 Ojeh N, Bharatha A, Gaur U, Forde AL. Keloids: current and emerging therapies, Scars Burn Heal. 2020 6 ;2059513120940499
    PubMedGoogle Scholar
  • 13 McGinty S, Siddiqui WJ. Keloid. Treasure Island, FL: StatPearls; 2021
    Google Scholar
  • 14 Bayat A, Arscott G, Ollier WE, McGrouther DA, Ferguson MW. Keloid disease: clinical relevance of single versus multiple site scars. Br J Plast Surg 2005; 58 (01) 28-37
    CrossrefPubMedGoogle Scholar
  • 15 Shih B, Bayat A. Genetics of keloid scarring. Arch Dermatol Res 2010; 302 (05) 319-339
    CrossrefPubMedGoogle Scholar
  • 16 Burd A, Huang L. Hypertrophic response and keloid diathesis: two very different forms of scar. Plast Reconstr Surg 2005; 116 (07) 150e-157e
    CrossrefPubMedGoogle Scholar
  • 17 Wolfram D, Tzankov A, Pülzl P, Piza-Katzer H. Hypertrophic scars and keloids--a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009; 35 (02) 171-181
    CrossrefPubMedGoogle Scholar
  • 18 Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007; 25 (01) 26-32
    CrossrefPubMedGoogle Scholar
  • 19 Cosman B, Crikelair G, Ju D, Gaulin J, Lattes R. The surgical treatment of keloids. Plast Reconstr Surg 1961; 27 (04) 335-358
    CrossrefPubMedGoogle Scholar
  • 20 Oluwasanmi JO. Keloids in the African. Clin Plast Surg 1974; 1 (01) 179-195
    CrossrefPubMedGoogle Scholar
  • 21 Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg 1989; 84 (05) 827-837
    CrossrefPubMedGoogle Scholar
  • 22 Sun LM, Wang KH, Lee YC. Keloid incidence in Asian people and its comorbidity with other fibrosis-related diseases: a nationwide population-based study. Arch Dermatol Res 2014; 306 (09) 803-808
    CrossrefPubMedGoogle Scholar
  • 23 Bloom D. Heredity of keloids; review of the literature and report of a family with multiple keloids in five generations. N Y State J Med 1956; 56 (04) 511-519
    PubMedGoogle Scholar
  • 24 Seifert O, Mrowietz U. Keloid scarring: bench and bedside. Arch Dermatol Res 2009; 301 (04) 259-272
    CrossrefPubMedGoogle Scholar
  • 25 Glass II DA. Current understanding of the genetic causes of keloid formation. J Investig Dermatol Symp Proc 2017; 18 (02) S50-S53
    CrossrefPubMedGoogle Scholar
  • 26 Ramakrishnan KM, Thomas KP, Sundararajan CR. Study of 1,000 patients with keloids in South India. Plast Reconstr Surg 1974; 53 (03) 276-280
    CrossrefPubMedGoogle Scholar
  • 27 Mouhari-Toure A, Saka B, Kombaté K. et al. Is there an association between keloids and blood groups?. ISRN Dermatol 2012; 2012: 750908-750908
    CrossrefPubMedGoogle Scholar
  • 28 Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137 (11) 1429-1434
    CrossrefPubMedGoogle Scholar
  • 29 Goeminne L. A new probably X-linked inherited syndrome: congenital muscular torticollis, multiple keloids cryptorchidism and renal dysplasia. Acta Genet Med Gemellol (Roma) 1968; 17 (03) 439-467
    CrossrefPubMedGoogle Scholar
  • 30 Omo-Dare P. Genetic studies on keloid. J Natl Med Assoc 1975; 67 (06) 428-432
    Google Scholar
  • 31 Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011; 17 (1-2): 113-125
    CrossrefPubMedGoogle Scholar
  • 32 Schmieder SJ, Ferrer-Bruker SJ. Hypertrophic Scarring. Treasure Island, FL: StatPearls; 2021
    Google Scholar
  • 33 Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet 2016; 388 (10052): 1427-1436
    CrossrefPubMedGoogle Scholar
  • 34 Frangogiannis N. Transforming growth factor-β in tissue fibrosis, J Exp Med. 2020 217. 03; e20190103
    PubMedGoogle Scholar
  • 35 Ogawa R, Akita S, Akaishi S. et al. Diagnosis and treatment of keloids and hypertrophic scars-Japan Scar Workshop Consensus Document 2018. Burns Trauma 2019; 7: 39-39
    CrossrefPubMedGoogle Scholar
  • 36 Naitoh M, Hosokawa N, Kubota H. et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun 2001; 280 (05) 1316-1322
    CrossrefPubMedGoogle Scholar
  • 37 Butler PD, Longaker MT, Yang GP. Current progress in keloid research and treatment. J Am Coll Surg 2008; 206 (04) 731-741
    CrossrefPubMedGoogle Scholar
  • 38 Hunasgi S, Koneru A, Vanishree M, Shamala R. Keloid: a case report and review of pathophysiology and differences between keloid and hypertrophic scars. J Oral Maxillofac Pathol 2013; 17 (01) 116-120
    CrossrefPubMedGoogle Scholar
  • 39 Halim AS, Emami A, Salahshourifar I, Kannan TP. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg 2012; 39 (03) 184-189
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 40 Rabello FB, Souza CD, Farina Júnior JA. Update on hypertrophic scar treatment. Clinics (São Paulo) 2014; 69 (08) 565-573
    CrossrefPubMedGoogle Scholar
  • 41 Nast A, Eming S, Fluhr J. et al; German Society of Dermatology. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges 2012; 10 (10) 747-762
    CrossrefPubMedGoogle Scholar
  • 42 Son D, Harijan A. Overview of surgical scar prevention and management. J Korean Med Sci 2014; 29 (06) 751-757
    CrossrefPubMedGoogle Scholar
  • 43 Bayat A, McGrouther DA, Ferguson MW. Skin scarring. BMJ 2003; 326 (7380): 88-92
    CrossrefPubMedGoogle Scholar
  • 44 Wong VW, Akaishi S, Longaker MT, Gurtner GC. Pushing back: wound mechanotransduction in repair and regeneration. J Invest Dermatol 2011; 131 (11) 2186-2196
    CrossrefPubMedGoogle Scholar
  • 45 Jiang Q, Chen J, Liu Z. Silicone gel sheeting for treating hypertrophic scars, Cochrane Database Syst Rev. 2019 2019. 06
    PubMedGoogle Scholar
  • 46 Hirshowitz B, Lindenbaum E, Har-Shai Y, Feitelberg L, Tendler M, Katz D. Static-electric field induction by a silicone cushion for the treatment of hypertrophic and keloid scars. Plast Reconstr Surg 1998; 101 (05) 1173-1183
    CrossrefPubMedGoogle Scholar
  • 47 Eishi K, Bae SJ, Ogawa F, Hamasaki Y, Shimizu K, Katayama I. Silicone gel sheets relieve pain and pruritus with clinical improvement of keloid: possible target of mast cells. J Dermatolog Treat 2003; 14 (04) 248-252
    CrossrefPubMedGoogle Scholar
  • 48 Reiffel RS. Prevention of hypertrophic scars by long-term paper tape application. Plast Reconstr Surg 1995; 96 (07) 1715-1718
    CrossrefPubMedGoogle Scholar
  • 49 Tollefson TT, Kamangar F, Aminpour S, Lee A, Durbin-Johnson B, Tinling S. Comparison of effectiveness of silicone gel sheeting with microporous paper tape in the prevention of hypertrophic scarring in a rabbit model. Arch Facial Plast Surg 2012; 14 (01) 45-51
    CrossrefPubMedGoogle Scholar
  • 50 Atkinson JA, McKenna KT, Barnett AG, McGrath DJ, Rudd M. A randomized, controlled trial to determine the efficacy of paper tape in preventing hypertrophic scar formation in surgical incisions that traverse Langer's skin tension lines. Plast Reconstr Surg 2005; 116 (06) 1648-1656 , discussion 1657–1658
    CrossrefPubMedGoogle Scholar
  • 51 Commander SJ, Chamata E, Cox J, Dickey RM, Lee EI. Update on postsurgical scar management. Semin Plast Surg 2016; 30 (03) 122-128
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 52 Lin Y-S, Ting P-S, Hsu K-C. Comparison of silicone sheets and paper tape for the management of postoperative scars: a randomized comparative study. Adv Skin Wound Care 2020; 33 (06) 1-6
    CrossrefPubMedGoogle Scholar
  • 53 Poetschke J, Gauglitz GG. Onion extract. In: Téot L, Mustoe TA, Middelkoop E, Gauglitz GG. eds. Textbook on Scar Management: State of the Art Management and Emerging Technologies. Cham: Springer International Publishing; 2020: 209-213
    CrossrefGoogle Scholar
  • 54 Phan TT, Lim IJ, Sun L. et al. Quercetin inhibits fibronectin production by keloid-derived fibroblasts. Implication for the treatment of excessive scars. J Dermatol Sci 2003; 33 (03) 192-194
    CrossrefPubMedGoogle Scholar
  • 55 Beuth J, Hunzelmann N, Van Leendert R, Basten R, Noehle M, Schneider B. Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany. In Vivo 2006; 20 (02) 277-283
    PubMedGoogle Scholar
  • 56 Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg 2006; 32 (02) 193-197
    PubMedGoogle Scholar
  • 57 Jackson BA, Shelton AJ. Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol Surg 1999; 25 (04) 267-269
    CrossrefPubMedGoogle Scholar
  • 58 Svensjö T, Pomahac B, Yao F, Slama J, Eriksson E. Accelerated healing of full-thickness skin wounds in a wet environment. Plast Reconstr Surg 2000; 106 (03) 602-612 , discussion 613–614
    CrossrefPubMedGoogle Scholar
  • 59 Haedersdal M, Bech-Thomsen N, Poulsen T, Wulf HC. Ultraviolet exposure influences laser-induced wounds, scars, and hyperpigmentation: a murine study. Plast Reconstr Surg 1998; 101 (05) 1315-1322
    CrossrefPubMedGoogle Scholar
  • 60 Due E, Rossen K, Sorensen LT, Kliem A, Karlsmark T, Haedersdal M. Effect of UV irradiation on cutaneous cicatrices: a randomized, controlled trial with clinical, skin reflectance, histological, immunohistochemical and biochemical evaluations. Acta Derm Venereol 2007; 87 (01) 27-32
    CrossrefPubMedGoogle Scholar
  • 61 Gold MH, McGuire M, Mustoe TA. et al; International Advisory Panel on Scar Management. Updated international clinical recommendations on scar management: part 2--algorithms for scar prevention and treatment. Dermatol Surg 2014; 40 (08) 825-831
    PubMedGoogle Scholar
  • 62 Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47 (4, Suppl): S209-S211
    CrossrefPubMedGoogle Scholar
  • 63 Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. J Med Assoc Thai 2007; 90 (07) 1363-1367
    PubMedGoogle Scholar
  • 64 Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg 2009; 35 (04) 629-633
    CrossrefPubMedGoogle Scholar
  • 65 Berman B, Harrison-Balestra C, Perez OA. et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: a prospective, double-blind, placebo-controlled pilot study. J Drugs Dermatol 2009; 8 (05) 455-458
    PubMedGoogle Scholar
  • 66 Bubna AK. Imiquimod - its role in the treatment of cutaneous malignancies. Indian J Pharmacol 2015; 47 (04) 354-359
    CrossrefPubMedGoogle Scholar
  • 67 Verhiel S, Piatkowski de Grzymala A, van der Hulst R. Mechanism of action, efficacy, and adverse events of calcium antagonists in hypertrophic scars and keloids: a systematic review. Dermatol Surg 2015; 41 (12) 1343-1350
    CrossrefPubMedGoogle Scholar
  • 68 Danielsen PL, Rea SM, Wood FM. et al. Verapamil is less effective than triamcinolone for prevention of keloid scar recurrence after excision in a randomized controlled trial. Acta Derm Venereol 2016; 96 (06) 774-778
    PubMedGoogle Scholar
  • 69 Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008; 74 (04) 343-348
    CrossrefPubMedGoogle Scholar
  • 70 Atiyeh BS. Nonsurgical management of hypertrophic scars: evidence-based therapies, standard practices, and emerging methods. Aesthetic Plast Surg 2007; 31 (05) 468-492 , discussion 493–494
    CrossrefPubMedGoogle Scholar
  • 71 Gholizadeh N, Sadrzadeh-Afshar M-S, Sheykhbahaei N. Intralesional corticosteroid injection as an effective treatment method for oral lesions: a meta-analysis. Braz J Pharm Sci 2020; •••: 56-56
    PubMedGoogle Scholar
  • 72 Boyadjiev C, Popchristova E, Mazgalova J. Histomorphologic changes in keloids treated with Kenacort. J Trauma 1995; 38 (02) 299-302
    CrossrefPubMedGoogle Scholar
  • 73 Cruz NI, Korchin L. Inhibition of human keloid fibroblast growth by isotretinoin and triamcinolone acetonide in vitro. Ann Plast Surg 1994; 33 (04) 401-405
    CrossrefPubMedGoogle Scholar
  • 74 Firooz A, Tehranchi-Nia Z, Ahmed AR. Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases. Clin Exp Dermatol 1995; 20 (05) 363-370
    CrossrefPubMedGoogle Scholar
  • 75 Lumenta DB, Siepmann E, Kamolz LP. Internet-based survey on current practice for evaluation, prevention, and treatment of scars, hypertrophic scars, and keloids. Wound Repair Regen 2014; 22 (04) 483-491
    CrossrefPubMedGoogle Scholar
  • 76 Juckett G, Hartman-Adams H. Management of keloids and hypertrophic scars. Am Fam Physician 2009; 80 (03) 253-260
    PubMedGoogle Scholar
  • 77 Bijlard E, Steltenpool S, Niessen FB. Intralesional 5-fluorouracil in keloid treatment: a systematic review. Acta Derm Venereol 2015; 95 (07) 778-782
    PubMedGoogle Scholar
  • 78 Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg 2013; 39 (12) 1745-1757
    CrossrefPubMedGoogle Scholar
  • 79 Jones CD, Guiot L, Samy M, Gorman M, Tehrani H. The use of chemotherapeutics for the treatment of keloid scars. Dermatol Rep 2015; 7 (02) 5880-5880
    CrossrefPubMedGoogle Scholar
  • 80 Seo SH, Sung HW. Treatment of keloids and hypertrophic scars using topical and intralesional mitomycin C. J Eur Acad Dermatol Venereol 2012; 26 (05) 634-638
    CrossrefPubMedGoogle Scholar
  • 81 Mandour Y, Bake H, Mofty E. et al. Topical versus interlesional mitomycin C in auricular keloids, Acta Otorrinolaringol Esp (Engl Ed). 2020 S0001-6519(20)30154-0
    PubMedGoogle Scholar
  • 82 Har-Shai Y, Amar M, Sabo E. Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. Plast Reconstr Surg 2003; 111 (06) 1841-1852
    CrossrefPubMedGoogle Scholar
  • 83 Levy LL, Zeichner JA. Management of acne scarring, part II: a comparative review of non-laser-based, minimally invasive approaches. Am J Clin Dermatol 2012; 13 (05) 331-340
    CrossrefPubMedGoogle Scholar
  • 84 O'Boyle CP, Shayan-Arani H, Hamada MW. Intralesional cryotherapy for hypertrophic scars and keloids: a review, Scars Burn Heal. 2017 3 ;2059513117702162
    PubMedGoogle Scholar
  • 85 van Leeuwen MC, Bulstra AE, Ket JC, Ritt MJ, van Leeuwen PA, Niessen FB. Intralesional cryotherapy for the treatment of keloid scars: evaluating effectiveness. Plast Reconstr Surg Glob Open 2015; 3 (06) e437-e437
    CrossrefPubMedGoogle Scholar
  • 86 Zouboulis CC, Blume U, Büttner P, Orfanos CE. Outcomes of cryosurgery in keloids and hypertrophic scars. A prospective consecutive trial of case series. Arch Dermatol 1993; 129 (09) 1146-1151
    CrossrefPubMedGoogle Scholar
  • 87 McGoldrick RB, Theodorakopoulou E, Azzopardi EA, Murison M. Lasers and ancillary treatments for scar management Part 2: keloid, hypertrophic, pigmented and acne scars, Scars Burn Heal. 2017 3 ;2059513116689805
    PubMedGoogle Scholar
  • 88 Litrowski N, Boullie MC, Dehesdin D, De Barros A, Joly P. Treatment of earlobe keloids by surgical excision and cryosurgery. J Eur Acad Dermatol Venereol 2014; 28 (10) 1324-1331
    CrossrefPubMedGoogle Scholar
  • 89 Wilson AM. Eradication of keloids: surgical excision followed by a single injection of intralesional 5-fluorouracil and botulinum toxin. Can J Plast Surg 2013; 21 (02) 87-91
    CrossrefPubMedGoogle Scholar
  • 90 Khan FA, Drucker NA, Larson SD, Taylor JA, Islam S. Pediatric earlobe keloids: outcomes and patterns of recurrence. J Pediatr Surg 2020; 55 (03) 461-464
    CrossrefPubMedGoogle Scholar
  • 91 Lee SY, Park J. Postoperative electron beam radiotherapy for keloids: treatment outcome and factors associated with occurrence and recurrence. Ann Dermatol 2015; 27 (01) 53-58
    CrossrefPubMedGoogle Scholar
  • 92 Oosterhoff TCH, Beekman VK, van der List JP, Niessen FB. Laser treatment of specific scar characteristics in hypertrophic scars and keloid: a systematic review. J Plast Reconstr Aesthet Surg 2021; 74 (01) 48-64
    CrossrefPubMedGoogle Scholar
  • 93 Alster TS, Handrick C. Laser treatment of hypertrophic scars, keloids, and striae. Semin Cutan Med Surg 2000; 19 (04) 287-292
    CrossrefPubMedGoogle Scholar
  • 94 Bhusari P, Shukla J, Kumar M. et al. Noninvasive treatment of keloid using customized Re-188 skin patch, Dermatol Ther (Heidelb). 2017; 30 (05) DOI: 10.1111/dth.12515.
    CrossrefPubMedGoogle Scholar
  • 95 Mankowski P, Kanevsky J, Tomlinson J, Dyachenko A, Luc M. Optimizing radiotherapy for keloids: a meta-analysis systematic review comparing recurrence rates between different radiation modalities. Ann Plast Surg 2017; 78 (04) 403-411
    CrossrefPubMedGoogle Scholar
  • 96 Ogawa R, Mitsuhashi K, Hyakusoku H, Miyashita T. Postoperative electron-beam irradiation therapy for keloids and hypertrophic scars: retrospective study of 147 cases followed for more than 18 months. Plast Reconstr Surg 2003; 111 (02) 547-553 , discussion 554–555
    PubMedGoogle Scholar
  • 97 Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 2000; 105 (06) 1948-1953 , discussion 1954–1955
    CrossrefPubMedGoogle Scholar
  • 98 Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg 2009; 124 (05) 275e-277e
    CrossrefPubMedGoogle Scholar
  • 99 Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg 2009; 33 (03) 409-412
    CrossrefPubMedGoogle Scholar
  • 100 Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol 2015; 14 (02) 161-166
    CrossrefPubMedGoogle Scholar
  • 101 Zonari A, Martins TM, Paula AC. et al. Polyhydroxybutyrate-co-hydroxyvalerate structures loaded with adipose stem cells promote skin healing with reduced scarring. Acta Biomater 2015; 17: 170-181
    CrossrefPubMedGoogle Scholar
  • 102 Bojanic C, To K, Hatoum A. et al. Mesenchymal stem cell therapy in hypertrophic and keloid scars. Cell Tissue Res 2021; 383 (03) 915-930
    CrossrefPubMedGoogle Scholar
  • 103 Lee G, Hunter-Smith DJ, Rozen WM. Autologous fat grafting in keloids and hypertrophic scars: a review, Scars Burn Heal. 2017 3; 2059513117700157
    PubMedGoogle Scholar
  • 104 Williams EA, Thaller SR. The role of fat grafting in the treatment of keloid scars and venous ulcers. J Craniofac Surg 2019; 30 (03) 696-697
    CrossrefPubMedGoogle Scholar
  • 105 Silva VZD, Albacete A, Horácio GS. et al. Evidences of autologous fat grafting for the treatment of keloids and hypertrophic scars. Rev Assoc Med Bras (1992) 2016; 62 (09) 862-866
    CrossrefPubMedGoogle Scholar
  • 106 Pallua N, Baroncini A, Alharbi Z, Stromps JP. Improvement of facial scar appearance and microcirculation by autologous lipofilling. J Plast Reconstr Aesthet Surg 2014; 67 (08) 1033-1037
    CrossrefPubMedGoogle Scholar
  • 107 Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997; 37 (5 Pt 1): 755-757
    CrossrefPubMedGoogle Scholar
  • 108 al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol 1996; 35 (07) 515-517
    CrossrefPubMedGoogle Scholar
  • 109 Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol 2008; 47 (02) 183-186
    CrossrefPubMedGoogle Scholar
  • 110 Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 1992; 339 (8787): 213-214
    CrossrefPubMedGoogle Scholar
  • 111 McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163 (10) 5693-5699
    CrossrefPubMedGoogle Scholar